Moreover, Paris saponin II (Figure 4) revealed anti-cancer activities against ovarian cancer via blocking NF-κB as one of the signaling pathways of inflammation and VEGF stimulant generation, thereby inhibiting angiogenesis in in vitro (2.5 μM) and in vivo (25 mg/kg, i.p., female Balb/c mice) [183,184]. The gene discussed is VEGFA; the disease is ovarian cancer.